(Q33377531)

26 July 2017

1 reference

title

Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? (English)

1 reference

Véronique Frémeaux-Bacchi

26 July 2017

1 reference

series ordinal

2

object named as

Véronique Frémeaux-Bacchi

1 reference

26 July 2017

Fadi Fakhouri

1

1 reference

26 July 2017

1 December 2007

1 reference

Nature Clinical Practice Nephrology

26 July 2017

1 reference

26 July 2017

3

1 reference

26 July 2017

12

1 reference

26 July 2017

679-687

1 reference

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

26 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Atypical haemolytic uraemic syndrome and mutations in complement regulator genes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Localization of ADAMTS13 to the stellate cells of human liver

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Measurement of ADAMTS13 activity and inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Clinical practice. Thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

The human complement factor H: functional roles, genetic variations and disease associations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Atypical haemolytic uraemic syndrome associated with a hybrid complement gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Rapid determination of ADAMTS13 activity improves clinical decision-making

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

A rapid enzyme-linked assay for ADAMTS-13.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0670

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0670

1 reference

26 July 2017

1 reference

PubMed ID

18033227